The efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy

被引：0
|
作者：
Saigusa, M. [1 ]
Sakurai, S. [1 ]
Akamatsu, T. [1 ]
Yamamoto, A. [1 ]
Shishido, Y. [1 ]
Akita, T. [1 ]
Morita, S. [1 ]
Asada, K. [1 ]
Shirai, T. [1 ]
Eto, T. [1 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Resp Med, Shizuoka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30294-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
184P
引用
收藏
页码：S137 / S137
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy
    Saigusa, Mika
    Asada, Kazuhiro
    Akamatsu, Taisuke
    Tanaka, Yuko
    Endo, Yoshinari
    Yamamoto, Akito
    Morita, Satoru
    Shirai, Toshihiro
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 52 - 56
  • [2] Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: A Feasible Therapeutic Option?
    Galetta, Domenico
    Rossi, Antonio
    Colucci, Giuseppe
    Gebbia, Vittorio
    [J]. ONCOLOGY, 2009, 77 : 113 - 121
  • [3] Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients Feasible Drugs for Feasible Patients
    Yu, Yongfeng
    Song, Zhengbo
    Wu, Chunxiao
    Lu, Shun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S403 - S403
  • [4] Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients
    Song, Zhengbo
    Yu, Yongfeng
    Chen, Zhiwei
    Lu, Shun
    [J]. MEDICAL ONCOLOGY, 2011, 28 : S605 - S612
  • [5] Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients
    Zhengbo Song
    Yongfeng Yu
    Zhiwei Chen
    Shun Lu
    [J]. Medical Oncology, 2011, 28 : 605 - 612
  • [6] Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    Corral Jaime, Jesus
    Gonzalez de la Pena, Miriam
    Alonso, Miriam
    Sanchez Gastaldo, Amparo
    Dolores Mediano, Maria
    Amerigo, Marta
    Enrique Robles, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Papadimitrakopoulou, Vassiliki A.
    Soria, Jean-Charles
    Jappe, Annette
    Jehl, Valentine
    Klimovsky, Judith
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1594 - 1601
  • [8] Efficacy and safety of Endostar (recombinant human endostatin hormone) combined with docetaxel as second-or third-line therapy for patients with non-small-cell lung cancer
    Ji, Dongmei
    Wang, Jialei
    Yu, Hui
    Wu, Xianghua
    Wang, Huijie
    Li, Wenhua
    Sun, Si
    Zhang, Jian
    Chang, Jianhua
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01): : 843 - 852
  • [9] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
    Shao, Yu-Yun
    Shau, Wen-Yi
    Lin, Zhong-Zhe
    Chen, Ho-Min
    Kuo, Raymond
    Yang, James Chih-Hsin
    Lai, Mei-Shu
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 106 - 114
  • [10] Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer
    Igawa, Satoshi
    Yamamoto, Nobuyuki
    Ueda, Shinya
    Ono, Akira
    Nakamura, Yukiko
    Tsuya, Asuka
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 741 - 744
12345